ArticleNeurogenetics2014
Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression.
Article in Neurogenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Meta-analysis of the Selected Genetic Variants in Immune-Related Genes and Multiple Sclerosis Risk.Molecular neurobiology · 2024Pooled it
- Innate lymphoid cells: unsung heroes or villains in multiple sclerosis pathogenesis?Immunologic research · 2026Review
- Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.Inflammopharmacology · 2025Review
- Multiple Sclerosis: New Insights into Molecular Pathogenesis and Novel Platforms for Disease Treatment.Current drug research reviews · 2024Review
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
- Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis.Scientific reports · 2021Observational
- Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent.ImmunoTargets and therapy · 2021Review
- Genetic analysis of nucleotide-binding leucine-rich repeat (NLR) receptors in multiple sclerosis.Immunogenetics · 2020Article
- Association of rs12487066, rs12044852, rs10735781, rs3135388, rs6897932, rs1321172, rs10492972, and rs9657904 Polymorphisms with Multiple Sclerosis in Iranian Population.Oman medical journal · 2020Article
- Association of Multiple Sclerosis Phenotypes with Single Nucleotide Polymorphisms ofBiomolecules · 2020Article
- Analysis of galanin receptor GALR2 in multiple sclerosis.The pharmacogenomics journal · 2019Article
- NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity.PLoS biology · 2019Article
- Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease.PLoS genetics · 2019Article
- Analysis of NOD-like receptor NLRP1 in multiple sclerosis families.Immunogenetics · 2018Article
- Identifying characteristic miRNAs-genes and risk pathways of multiple sclerosis based on bioinformatics analysis.Oncotarget · 2018Article
- Common genetic etiology between "multiple sclerosis-like" single-gene disorders and familial multiple sclerosis.Human genetics · 2017Article
- Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis.Human mutation · 2017Article
- Publicly Available Data Provide Evidence against NR1H3 R415Q Causing Multiple Sclerosis.Neuron · 2016Article
- Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.G3 (Bethesda, Md.) · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a common demyelinating neurodegenerative disease with a strong genetic component. Previous studies have associated genetic variants in IL2RA and IL7R in the pathophysiology of the disease. In this study, we describe the association between IL2RA (rs2104286) and IL7R (rs6897932) in the Canadian population. Genotyping 1,978 MS patients and 830 controls failed to identify any significant association between these variants and disease risk. However, stratified analysis for family history of disease and disease course identified a trend towards association for IL2RA in patients without a family history (p = 0.05; odds ratio = 0.77) and a significant association between IL7R and patients who developed progressive MS (PrMS) (p = 0.002; odds ratio = 0.73). Although not statistically significant, the effect of IL2RA (rs2104286) in patients without a family history of MS indicates that the genetic components for familial and sporadic disease are perhaps distinct. This data suggests that the onset of sporadic disease is likely determined by a large number of variants of small effect, whereas MS in patients with a family history of disease is caused by a few deleterious variants. In addition, the significant association between PrMS and rs6897932 indicates that IL7R may not be disease-causing but a determinant of disease course. Further characterization of the effect of IL2RA and IL7R genetic variants in defined MS subtypes is warranted to evaluate the effect of these genes on specific clinical outcomes and to further elucidate the mechanisms of disease onset and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.